Vanguard Personalized Indexing Management LLC Purchases 8,744 Shares of Abbott Laboratories (NYSE:ABT)

Vanguard Personalized Indexing Management LLC raised its holdings in shares of Abbott Laboratories (NYSE:ABT) by 6.2% in the second quarter, HoldingsChannel.com reports. The firm owned 149,827 shares of the healthcare product maker’s stock after buying an additional 8,744 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Abbott Laboratories were worth $15,279,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Unique Wealth Strategies LLC purchased a new position in Abbott Laboratories during the 2nd quarter worth $28,000. Redmont Wealth Advisors LLC purchased a new position in shares of Abbott Laboratories in the 1st quarter worth about $30,000. Richardson Financial Services Inc. purchased a new position in shares of Abbott Laboratories in the 4th quarter worth about $29,000. Transcendent Capital Group LLC purchased a new position in shares of Abbott Laboratories in the 4th quarter worth about $29,000. Finally, True Wealth Design LLC boosted its holdings in shares of Abbott Laboratories by 1,677.8% in the 4th quarter. True Wealth Design LLC now owns 320 shares of the healthcare product maker’s stock worth $35,000 after buying an additional 302 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 0.4 %

Shares of ABT stock opened at $118.13 on Wednesday. The company has a current ratio of 1.68, a quick ratio of 1.18 and a debt-to-equity ratio of 0.33. Abbott Laboratories has a twelve month low of $89.67 and a twelve month high of $121.64. The stock has a 50 day moving average of $109.88 and a 200 day moving average of $108.56. The stock has a market cap of $205.50 billion, a P/E ratio of 36.80, a P/E/G ratio of 2.90 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, July 18th. The healthcare product maker reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.04. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.65%. The company had revenue of $10.38 billion for the quarter, compared to the consensus estimate of $10.37 billion. During the same quarter in the previous year, the business earned $1.08 earnings per share. The company’s revenue for the quarter was up 4.0% on a year-over-year basis. As a group, sell-side analysts expect that Abbott Laboratories will post 4.66 EPS for the current year.

Insider Transactions at Abbott Laboratories

In related news, CEO Robert B. Ford sold 141,679 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $116.41, for a total value of $16,492,852.39. Following the sale, the chief executive officer now owns 220,059 shares in the company, valued at approximately $25,617,068.19. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 1.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on ABT shares. Evercore ISI cut their price target on shares of Abbott Laboratories from $125.00 to $120.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Barclays boosted their price objective on Abbott Laboratories from $140.00 to $143.00 and gave the company an “overweight” rating in a research note on Monday, July 29th. Royal Bank of Canada restated an “outperform” rating and issued a $125.00 price objective on shares of Abbott Laboratories in a research note on Tuesday, June 4th. Citigroup upped their price target on Abbott Laboratories from $119.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Finally, The Goldman Sachs Group began coverage on Abbott Laboratories in a research report on Thursday, May 30th. They set a “buy” rating and a $121.00 price target on the stock. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $121.80.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.